- Market Capitalization, $K 1,140,868
- Shares Outstanding, K 32,110
- Annual Sales, $ 0 K
- Annual Income, $ -111,830 K
- 60-Month Beta 1.11
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 8.96
|Period||Period Low||Period High||Performance|
| || |
+6.31 (+21.59%)since 05/05/20
| || |
+4.74 (+15.39%)since 03/05/20
| || |
+9.03 (+34.08%)since 06/05/19
Odonate Therapeutics (ODT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Odonate Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.
Zacks.com featured highlights include: Odonate Therapeutics, Novavax, Beazer Homes USA and NVIDIA
Odonate Therapeutics, Inc. (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Studies have shown that a majority of successful stocks see acceleration in earnings before an uptick in the stock price.
Jazz Pharmaceuticals (JAZZ) reports encouraging first-quarter 2019 earnings and revenues and maintains its guidance for 2019.
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Newmont Mining Corporation (NYSE:NEM),...
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Omnicom Group Inc. (NYSE:OMC),...
|Odonate Therapeutics Inc|
|Bioshares Biotech Clinical Trial|
|Micro-Cap Ishares ETF|
|US Innovative Healthcare Ishares Evolved ETF|
|Russell 2000 Growth Ishares ETF|
|Russell 2000 Growth Vanguard|